HeartBeam Names Timothy Cruickshank as Chief Financial Officer
September 10 2024 - 8:31AM
Business Wire
Seasoned MedTech Leader with Proven Track
Record of Strategic Planning, Financial Stewardship and Commercial
Success
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology
company focused on transforming cardiac care by providing powerful
cardiac insights wherever the patient is, announced the appointment
of Timothy Cruickshank as Chief Financial Officer (CFO), effective
immediately. Mr. Cruickshank brings more than 15 years of public
company experience with a focus on growing businesses with
disruptive technologies through authentic leadership, strategic
focus, data-driven decisions, and strong risk management and
governance. He succeeds long-time CFO Richard Brounstein, who has
been serving in an advisory capacity since retiring in
February.
“Tim has an outstanding record of delivering results and
creating value and will be a strong partner in ensuring we have a
solid financial position as we strive to make our vision to
transform the monitoring and detection of cardiac conditions a
reality,” said Branislav Vajdic, PhD, Chief Executive Officer and
Founder of HeartBeam. “We thank Rick for his leadership over the
past 9 years as he worked tirelessly to establish the strong
financial foundation for the company which will continue to serve
us well moving forward.”
HeartBeam has developed a cable-free, credit card-sized device
that captures the heart’s electrical signals from three dimensions
and is designed to be capable of synthesizing a 12-lead ECG. The
Company’s first 510(k) submission for its proprietary technology is
currently under review with the FDA and is the cornerstone
submission upon which future submissions will be based. The Company
has 13 issued US patents and 4 issued international patents
supporting the underlying technology.
“The ability of HeartBeam’s unique technology to unlock
actionable heart intelligence from three dimensions for a range of
cardiac conditions is truly compelling to me,” said Mr.
Cruickshank. “I am excited to join the Company at this pivotal time
and look forward to working with the team to commercialize this
impactful innovation, drive financial excellence and expand our
impact to ultimately improving cardiac care for patients.”
Mr. Cruickshank, age 43, was a financial executive of ImpediMed
since 2008 and served as CFO from October 2019 through March 2024.
ImpediMed is a medical technology company that designs and
manufactures medical devices and software services employing its
pioneering bioimpedance spectroscopy (BIS) technology for multiple
indications including heart failure, protein calorie malnutrition,
and lymphedema within oncology. During Mr. Cruickshank’s time at
ImpediMed, he spearheaded the evolution of the company from a
traditional medical device company to a medical technology company
with a high margin Software-as-a-Service (SaaS) business model,
through the launch of the SOZO® Digital Health Platform. He
received a Master of Business Administration from Keller Graduate
School of Management and a Bachelor of Science in Accounting from
Syracuse University.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company
dedicated to transforming cardiac care by providing powerful
cardiac insights wherever the patient is. The Company is creating
the first ever cable-free 12-lead ECG capable of capturing the
heart’s electrical signals from three dimensions. This platform
technology is designed to be used in portable devices that can be
used wherever the patient is to deliver actionable heart
intelligence. Physicians will be able to identify cardiac health
trends and acute conditions and direct patients to the appropriate
care – all outside of a medical facility, thus redefining the
future of cardiac health management. The Company holds 13 US and 4
international issued patents related to technology enablement.
For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our Forms 10-K, 10-Q and other reports filed with the SEC and
available at www.sec.gov. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910912946/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us Media Contact: media@heartbeam.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Oct 2024 to Nov 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Nov 2023 to Nov 2024